liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden
Karolinska Institutet, Stockholm; Karolinska University Hospital, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Karolinska University Hospital, Stockholm, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Cardiology in Linköping.ORCID iD: 0000-0001-6353-8041
Show others and affiliations
2014 (English)In: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 175, no 1, 55-61 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND/OBJECTIVES: Levosimendan is used in acute heart failure (HF) and increasingly as planned repetitive infusions in stable chronic HF, but the extent of this practice is unknown. The aim was to assess the use of levosimendan vs. conventional inotropes and the use as planned repetitive vs. acute treatment, in Sweden.

METHODS: We performed a descriptive study with individual patient validation assessing the use of levosimendan and conventional intravenous inotropes, indications for levosimendan, clinical characteristics and survival in the Swedish Heart Failure Registry between 2000 and 2011. For repetitive levosimendan, we assessed potential indications for alternative interventions.

RESULTS: Of 53,548 total registrations, there were 655 confirmed with inotrope use (597 levosimendan, 37 conventional, 21 both) from 22 hospitals responding to validation, and 6069 in-patient controls with New York Heart Association III-IV and ejection fraction <40%. The indications for levosimendan were acute HF in 384 registrations (306 patients), and planned repetitive in 234 registrations (87 patients). Planned repetitive as a proportion of total levosimendan registrations ranged 0-65% and of total levosimendan patients ranged 0-54% in different hospitals. Of planned repetitive patients without existing cardiac resynchronization therapy, implantable cardioverter defibrillator, transplant and/or assist device, 46-98% were potential candidates for such interventions.

CONCLUSION: In HF in cardiology and internal medicine in Sweden, levosimendan was the overwhelming inotrope of choice, and the use of planned repetitive levosimendan was extensive, highly variable between hospitals and may have pre-empted other interventions. Potential effects of and indications for planned repetitive levosimendan need to be evaluated in prospective studies.

Place, publisher, year, edition, pages
Elsevier, 2014. Vol. 175, no 1, 55-61 p.
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-109611DOI: 10.1016/j.ijcard.2014.04.243ISI: 000339790700016PubMedID: 24820737OAI: diva2:739498

Funding agencies|Swedish National Board of Health and Welfare; Swedish Association of Local Authorities and Regions; Swedish Society of Cardiology; Swedish Heart- Lung Foundation; Swedish Heart- Lung Foundation [20080409, 20100419]; Stockholm County Council [00556-2009, 20110120]; OrionPharma Inc.

Available from: 2014-08-21 Created: 2014-08-21 Last updated: 2014-09-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Division of Cardiovascular MedicineFaculty of Health SciencesDepartment of Cardiology in Linköping
In the same journal
International Journal of Cardiology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link